Media coverage about Viveve Medical (NASDAQ:VIVE) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Viveve Medical earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 43.4915853401072 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of analysts recently weighed in on VIVE shares. Ladenburg Thalmann Financial Services reiterated a “buy” rating on shares of Viveve Medical in a report on Thursday, January 4th. ValuEngine downgraded shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Mizuho reiterated a “buy” rating and issued a $10.00 target price on shares of Viveve Medical in a report on Friday, January 5th. Northland Securities began coverage on shares of Viveve Medical in a report on Friday, January 5th. They issued an “outperform” rating and a $8.00 target price for the company. Finally, Cowen set a $11.00 target price on shares of Viveve Medical and gave the stock a “buy” rating in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Viveve Medical has an average rating of “Buy” and an average target price of $10.00.
Viveve Medical (NASDAQ:VIVE) opened at $4.49 on Monday. Viveve Medical has a fifty-two week low of $3.75 and a fifty-two week high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. The firm has a market cap of $87.22, a P/E ratio of -2.08 and a beta of -0.66.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The company had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $4.10 million. During the same quarter in the prior year, the company posted ($0.46) EPS. The company’s revenue for the quarter was up 120.1% on a year-over-year basis. analysts expect that Viveve Medical will post -2.05 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Viveve Medical (VIVE) Given Daily News Impact Rating of 0.14” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/29/viveve-medical-vive-given-daily-news-impact-rating-of-0-14.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.